Amgen selling Japanese rights to some drugs
Biotechnology giant Amgen is selling the Japanese rights to up to 13 of its experimental drugs to Takeda Pharmaceutical of Japan in a deal that might bring Amgen more than $1 billion.
Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug.